<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02696096</url>
  </required_header>
  <id_info>
    <org_study_id>793387</org_study_id>
    <nct_id>NCT02696096</nct_id>
  </id_info>
  <brief_title>Neuroimaging Predictors of Relapse During Treatment for Opiate Dependence</brief_title>
  <official_title>Neuroimaging Predictors of Relapse During Treatment for Opiate Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Butler Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Butler Hospital</source>
  <brief_summary>
    <textblock>
      This study proposes to use functional magnetic resonance imaging (FMRI) to observe brain&#xD;
      activity and behavior associated with decision-making about rewards (DD task), working memory&#xD;
      and working memory cognitive persistence (WM task), and craving (CR task) in 72 opiate&#xD;
      dependent participants initiating buprenorphine. While stably using opiates (initial study&#xD;
      appointment) and again during withdrawal (approximately 3 days later), participants will&#xD;
      receive an FMRI scan with behavioral challenges; immediately after the second FMRI, they will&#xD;
      receive their first dose of buprenorphine. Buprenorphine treatment will continue for twelve&#xD;
      weeks, followed by a four week taper. Urine toxicological analysis will be performed prior to&#xD;
      the first scanning session, weekly for two weeks and biweekly thereafter.&#xD;
&#xD;
      Participation for all individuals will last 4 months. Assessments will occur at baseline, and&#xD;
      weeks 1, 2, 4, 8, and 12. Buprenorphine induction will begin at the completion of the second&#xD;
      scan; follow-up medical visits will align with study assessments on weeks 1, 2, 4, 8 and 12.&#xD;
      All participants will receive 16 weeks of buprenorphine (the final 4 of these 16 weeks will&#xD;
      include a taper).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2016</start_date>
  <completion_date type="Actual">February 2020</completion_date>
  <primary_completion_date type="Actual">February 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>length of time to use opioid after buprenorphine initiated</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>length of time to return to opioid use after buprenorphine initiated</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Opioid Addiction</condition>
  <arm_group>
    <arm_group_label>All Participants</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>FMRI Suboxone</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>FMRI</intervention_name>
    <description>all participants will complete 2 FMRIs</description>
    <arm_group_label>All Participants</arm_group_label>
    <other_name>functional magnetic resonance imaging</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Suboxone</intervention_name>
    <description>all participants will be prescribed Suboxone for 4 months during their study participation</description>
    <arm_group_label>All Participants</arm_group_label>
    <other_name>buprenorphine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  opiate dependent persons&#xD;
&#xD;
          -  21-50 years old&#xD;
&#xD;
          -  interested in initiating outpatient buprenorphine treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  current methadone maintenance treatment program participation&#xD;
&#xD;
          -  medically necessary prescription opiate treatment (e.g., for chronic pain)&#xD;
&#xD;
          -  current criteria for a DSM-V diagnosis of substance dependence for sedative or&#xD;
             hypnotic drugs, alcohol, stimulants, cocaine, inhalants, hallucinogens&#xD;
&#xD;
          -  diagnosis of organic brain disorder, bipolar disorder, schizophrenia,&#xD;
             schizo-affective, schizophreniform or paranoid disorder&#xD;
&#xD;
          -  current suicidality on the Modified Scale for Suicidal Ideation&#xD;
&#xD;
          -  evidence of neuropsychological dysfunction as assessed by the study physician with&#xD;
             confirmation with the Folstein Mini-Mental Status Examinationâ€¢&#xD;
&#xD;
          -  anticipated major painful event (significant surgical procedure) in the coming 4&#xD;
             months&#xD;
&#xD;
          -  probation or parole requirements or an upcoming move that might interfere with&#xD;
             protocol participation&#xD;
&#xD;
          -  history of allergic reaction to buprenorphine or naloxone&#xD;
&#xD;
          -  currently pregnant or planning to become pregnant in the next 4 months&#xD;
&#xD;
          -  history of neurological disorder (e.g., epilepsy, stroke, brain injury)&#xD;
&#xD;
          -  impaired uncorrected vision&#xD;
&#xD;
          -  FMRI contraindications (e.g., claustrophobia, specific metallic implants and injuries)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Butler Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>February 9, 2016</study_first_submitted>
  <study_first_submitted_qc>February 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2016</study_first_posted>
  <last_update_submitted>May 11, 2020</last_update_submitted>
  <last_update_submitted_qc>May 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Butler Hospital</investigator_affiliation>
    <investigator_full_name>Michael Stein, MD</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
    <mesh_term>Buprenorphine, Naloxone Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

